ArticlePloS one2026
Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile multiple studies report that the BNT162b2 XBB.1.5-adapted mRNA COVID-19 vaccine (BNT162b2 XBB vaccine) is effective in preventing COVID-19 hospitalisation and death, effectiveness beyond six months remains unexplored.
methodsWe extended our previous study of BNT162b2 XBB vaccine effectiveness (VE) to evaluate durability against JN.1-related hospitalisation up to 46 weeks since dose using the id.DRIVE platform across Europe. This multi-country, multi-centre test-negative case-control study assessed the effectiveness and durability of the BNT162b2 XBB vaccine in preventing JN.1-associated hospitalisation among adults with severe acute respiratory infection between October 2023 and August 2024. Each case was matched with up to four controls by symptom onset date and study site. Multivariable analyses were adjusted for symptom onset date, age, sex, number of chronic conditions, and influenza vaccination receipt.
resultsAmong 827 test-positive cases and 2232 test-negative controls, protection against hospitalisation was sustained from two to <30 weeks since dose, with evidence of significant waning thereafter. VE was 64.5% (95% CI: 56.6; 71.0) at two to <30 weeks, and 4.9% (95% CI: -30.3; 30.7) at 30 to <46 weeks.
conclusionDespite the vaccine target not matching the predominant subvariant, BNT162b2 XBB vaccine protected against JN.1-related hospitalisation for up to 30 weeks. Protection against hospitalisation was non-significant after 30 weeks since dose, potentially due to further shift in circulating SARS-CoV-2 strains and/or waning immunity. Given the high COVID-19 activity in Europe during summer 2024, an additional vaccination after six months is warranted for those at risk of COVID-19 hospitalisation to maintain year-round protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.